Capstone Investment Advisors
SAGE

Capstone Investment Advisors’s Sage Therapeutics SAGE Stock Holding History

Capstone Investment Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-34,067
Closed -$370K – 2172
2024
Q2 		$370K Buy
+34,067
New +$437K ﹤0.01% 1471

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Capstone Investment Advisors's SAGE Position: Q3 2024 in Review

Capstone Investment Advisors sold out of Sage Therapeutics (SAGE) in Q3 2024, closing a stake of 34,067 shares — an estimated $370K sold.

Capstone Investment Advisors first reported a position in SAGE in Q2 2024 and held it in 1 quarter. The position peaked at $370K in Q2 2024. 176 funds tracked by Wall St. Rank hold SAGE as of Q3 2024.

  • Capstone Investment Advisors reported no remaining Sage Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 34,067 Sage Therapeutics shares in Q3 2024, an estimated $370K.
  • Capstone Investment Advisors first reported a position in Sage Therapeutics in Q2 2024 and held it in 1 quarter.
  • Capstone Investment Advisors's Sage Therapeutics position peaked at $370K in Q2 2024.
  • 176 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2024.

Based on Capstone Investment Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.